Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVP Followed by Tositumomab and Iodine I-131 Tositumomab in Untreated Low-grade NHL
NCT01663714Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2000
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tositumomab and iodine i 131 tositumomab in non-Hodgkin lymphoma (NHL), sponsored by GSK. Primary endpoints: Overall Response Rate (Unconfirmed) at 130 months and Overall Response Rate (Confirmed) at 130 months. Started Feb 2000; status: completed.
02
Drugs
tositumomabiodine i 131 tositumomab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01663714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663714.